NEW YORK (GenomeWeb) – Lucigen this week announced an exclusive distribution agreement with Sigma-Aldrich's Indian subsidiary.
The deal with Sigma-Aldrich Chemicals Private expands the market for Lucigen's life science reagents in that country, the Middleton, Wisconsin-based firm said. Financial and other terms of the agreement were not disclosed.
According to Lucigen CEO and Chairman Ralph Kauten, Sigma-Aldrich's market knowledge and logistics operations in India will allow his firm to provide researchers there with technologies for use with next-generation sequencing, cloning, and protein expression systems.
Lucigen recently raised $2.2 million in a private stock placement aimed at developing its ClariLight molecular diagnostics platform.